Genetic Therapy for Intervertebral Disc Degeneration.

Area of Science:

• Regenerative Medicine
• Molecular Biology
• Orthopedics

Background:

• Chronic lower back pain (LBP) is often caused by intervertebral disc degeneration (IVDD).
• Current LBP treatments have limitations, driving interest in biological therapies like stem cells and growth factors.
• Gene therapy presents a novel biological approach for IVDD treatment, though it is still in early development.

Purpose of the Study:

• To provide an overview of the principles and current status of gene therapy for IVDD.
• To review gene transfer techniques in degenerated disc cells and animal models.
• To discuss emerging gene therapy strategies including RNA interference and CRISPR gene editing.

Main Methods:

• Conducted literature searches using PubMed and Google Scholar.
• Reviewed studies on gene transfer to degenerated disc cells in vitro and in vivo.
• Examined applications of RNA interference (RNAi) and CRISPR gene editing systems.
• Investigated the role of mammalian target of rapamycin (mTOR) signaling in IVDD models.

Main Results:

• Gene transfer to degenerated disc cells shows potential in preclinical studies.
• RNA interference and CRISPR gene editing are being explored for targeted gene modulation in IVDD.
• mTOR signaling pathways are implicated in IVDD and are targets for therapeutic intervention.
• Technological advancements are paving the way for intradiscal gene therapy.

Conclusions:

• Gene therapy holds significant promise for treating chronic discogenic lower back pain.
• Intradiscal gene therapy represents a new generation of treatment options for IVDD.
• Further research and development are needed to translate these findings into clinical practice.